305(top 1%)
PR articles
22.2K(top 1%)
PR citations
68(top 1%)
PR h-index
74(top 1%)
h-index
350
documents
27.9K
doc citations
3.5K
citing journals
100
times ranked

Publications

307 peer-reviewed articles • 24,143 peer-reviewed citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Neuropsychiatric symptoms in systemic lupus erythematosus: mixed methods analysis of patient-derived attributional evidence in the international INSPIRE project
Rheumatology, 2025, 64, 1179-1192
1.96Citations (PDF)
2Cutaneous vasculitis in systemic lupus erythematosus: epidemiology and risk factors over a 20-year follow-up
Rheumatology, 2025, 64, 2749-2755
1.91Citations (PDF)
3‘I still can’t forget those words’: mixed methods study of the persisting impact on patients reporting psychosomatic and psychiatric misdiagnoses
Rheumatology, 2025, 64, 3842-3853
1.99Citations (PDF)
4IMMUNOSUPPRESSANTS AND LUPUS-RELATED DAMAGE: A PROPENSITY SCORE ANALYSIS OF THE BIRMINGHAM LUPUS COHORT
Journal of Rheumatology, 2025, 52, 250.2-250
2.30Citations (PDF)
5EFAVALEUKIN ALFA IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A BAYESIAN ADAPTIVE, PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED DOSE-RANGING STUDY
Journal of Rheumatology, 2025, 52, 253.1-253
2.30Citations (PDF)
6POS1181 IMPACT OF IMMUNOSUPPRESSIVE MEDICATIONS ON LUPUS-RELATED DAMAGE: A PROPENSITY SCORE ANALYSIS OF THE BIRMINGHAM LUPUS COHORT
Annals of the Rheumatic Diseases, 2025, 84, 1249-1250
6.90Citations (PDF)
7Prevalence and identification of neuropsychiatric symptoms in systemic autoimmune rheumatic diseases: an international mixed methods study
Rheumatology, 2024, 63, 1259-1272
1.970Citations (PDF)
8British Society of Rheumatology guideline working group response to European Medicines Agency safety update on Hydroxychloroquine
Rheumatology, 2024, 63, e37-e38
1.95Citations (PDF)
9Economic insecurities and patient-reported outcomes in patients with systemic lupus erythematosus in the USA: a cross-sectional analysis of data from the California Lupus Epidemiology Study
Lancet Rheumatology, The, 2024, 6, e105-e114
11.416Citations (PDF)
10Pandemic lockdowns: who feels coerced and why? - a study on perceived coercion, perceived pressures and procedural justice during the UK COVID-19 lockdowns
BMC Public Health, 2024, 24,
3.10Citations (PDF)
11P158 Cutaneous vasculitis in systemic lupus erythematosus: trends of incidence and risk factors
Rheumatology, 2024, 63,
1.90Citations (PDF)
12Evaluation of the EULAR/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population‐Based Registry
Arthritis Care and Research, 2023, 75, 1007-1016
2.85Citations (PDF)
13Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine
Rheumatology, 2023, 62, 1124-1135
1.917Citations (PDF)
14British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: comorbidity medications used in rheumatology practice
Rheumatology, 2023, 62, e89-e104
1.937Citations (PDF)
15Executive Summary: British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids
Rheumatology, 2023, 62, 1370-1387
1.928Citations (PDF)
16British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids
Rheumatology, 2023, 62, e48-e88
1.9193Citations (PDF)
17Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trial
Lancet Rheumatology, The, 2023, 5, e24-e35
11.433Citations (PDF)
18Population-based prevalence and incidence estimates of mixed connective tissue disease from the Manhattan Lupus Surveillance Program
Rheumatology, 2023, 62, 2845-2849
1.94Citations (PDF)
19Perceived Stress and Prediction of Worse Disease Activity and Symptoms in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort
Arthritis Care and Research, 2023, 75, 1681-1689
2.822Citations (PDF)
20The association of trauma with self-reported flares and disease activity in systemic lupus erythematosus (SLE)
Rheumatology, 2023, 62, 2780-2788
1.913Citations (PDF)
21Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling
Arthritis Care and Research, 2023, 75, 1859-1870
2.82Citations (PDF)
22OA25 Identification of biomarkers to stratify response to combination therapy with belimumab and rituximab in a randomized trial, BEAT-LUPUS for systemic lupus erythematosus
Rheumatology, 2023, 62,
1.90Citations (PDF)
23Medication Cost Concerns and Disparities in Patient-Reported Outcomes Among a Multiethnic Cohort of Patients With Systemic Lupus Erythematosus
Journal of Rheumatology, 2023, 50, 1302-1309
2.36Citations (PDF)
24Cost-related prescription non-adherence and patient-reported outcomes in systemic lupus erythematosus: The Michigan Lupus Epidemiology & Surveillance program
Lupus, 2023, 32, 1075-1083
1.75Citations (PDF)
25Association Between Severe Nonadherence to Hydroxychloroquine and Systemic Lupus Erythematosus Flares, Damage, and Mortality in 660 Patients From the SLICC Inception Cohort
Arthritis and Rheumatology, 2023, 75, 2195-2206
6.140Citations (PDF)
26Predictors of British Isles Lupus Assessment Group-based outcomes in patients with systemic lupus erythematosus: Analysis from the Systemic Lupus International Collaborating Clinics Inception Cohort
Lupus, 2023, 32, 1043-1055
1.72Citations (PDF)
27Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope
Rheumatology Advances in Practice, 2023, 7,
0.75Citations (PDF)
28Attribution of neuropsychiatric symptoms and prioritization of evidence in the diagnosis of neuropsychiatric lupus: mixed methods analysis of patient and clinician perspectives from the international INSPIRE study
Rheumatology, 2023, 63, 3471-3485
1.920Citations (PDF)
29Glucocorticoid-free Treatment of Systemic Lupus Erythematosus: Is it Feasible?
Indian Journal of Rheumatology, 2023, 18,
0.20Citations (PDF)
30Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index
Arthritis Care and Research, 2022, 74, 638-647
2.824Citations (PDF)
31Comparison of Responsiveness of British Isles Lupus Assessment Group 2004 Index, Systemic Lupus Erythematosus Disease Activity Index 2000, and British Isles Lupus Assessment Group 2004 Systems Tally
Arthritis Care and Research, 2022, 74, 1623-1630
2.810Citations (PDF)
32Medication decision-making and adherence in lupus: patient–physician discordance and the impact of previous ‘adverse medical experiences’
Rheumatology, 2022, 61, 1417-1429
1.925Citations (PDF)
33Telemedicine in rheumatology: a mixed methods study exploring acceptability, preferences and experiences among patients and clinicians
Rheumatology, 2022, 61, 2262-2274
1.978Citations (PDF)
34Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index
Rheumatology, 2022, 61, 4006-4015
1.939Citations (PDF)
35Will ‘the feeling of abandonment’ remain? Persisting impacts of the COVID-19 pandemic on rheumatology patients and clinicians
Rheumatology, 2022, 61, 3723-3736
1.913Citations (PDF)
36Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
Annals of the Rheumatic Diseases, 2022, 81, 370-378
6.994Citations (PDF)
37Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Annals of the Rheumatic Diseases, 2022, 81, 1143-1150
6.917Citations (PDF)
38The FATIGUE-PRO: a new patient-reported outcome instrument to quantify fatigue in patients affected by systemic lupus erythematosus
Rheumatology, 2022, 61, 3329-3340
1.95Citations (PDF)
39Chilblains in immune-mediated inflammatory diseases: a review
Rheumatology, 2022, 61, 4631-4642
1.934Citations (PDF)
40FC055: Effect of Atacicept on Renal Function in SLE Patients
Nephrology Dialysis Transplantation, 2022, 37,
0.80Citations (PDF)
41The BILAG-2004 index is associated with development of new damage in SLE
Rheumatology, 2022, 62, 668-675
1.95Citations (PDF)
42Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
Pharmacoeconomics, 2022, 40, 851-861
3.64Citations (PDF)
43The BILAG2004-Pregnancy Index is a valid disease activity outcome measure for pregnant SLE patients
Rheumatology Advances in Practice, 2022, 6,
0.74Citations (PDF)
44Access and Cost‐Related Nonadherence to Prescription Medications Among Lupus Patients and Controls: The Michigan Lupus Epidemiology and Surveillance Program
Arthritis Care and Research, 2021, 73, 1561-1567
2.822Citations (PDF)
45Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications
Arthritis Care and Research, 2021, 73, 1789-1795
2.831Citations (PDF)
46Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria
Arthritis Care and Research, 2021, 73, 1231-1235
2.826Citations (PDF)
47Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics
Annals of the Rheumatic Diseases, 2021, 80, 1-2
6.934Citations (PDF)
48BSR guideline on the management of adults with systemic lupus erythematosus (SLE) 2018: baseline multi-centre audit in the UK
Rheumatology, 2021, 60, 1480-1490
1.99Citations (PDF)
49Estimation of the burden of shielding among a cross-section of patients attending rheumatology clinics with SLE—data from the BSR audit of systemic lupus erythematosus
Rheumatology, 2021, 60, 1474-1479
1.99Citations (PDF)
50COVID-19 and shielding: experiences of UK patients with lupus and related diseases
Rheumatology Advances in Practice, 2021, 5,
0.733Citations (PDF)
51Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort
Rheumatology, 2021, 60, 4737-4747
1.924Citations (PDF)
52Prescribing anti-rheumatic drugs in pregnancy and breastfeeding—the British Society for Rheumatology guideline scope
Rheumatology, 2021, 60, 3565-3569
1.96Citations (PDF)
53Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta‐Analysis of the Centers for Disease Control and Prevention National Lupus Registries
Arthritis and Rheumatology, 2021, 73, 991-996
6.1249Citations (PDF)
54O19 Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004
Rheumatology, 2021, 60,
1.90Citations (PDF)
55Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset
Lupus, 2021, 30, 1283-1288
1.76Citations (PDF)
56Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort
Arthritis and Rheumatology, 2021, 73, 2293-2302
6.122Citations (PDF)
57Understanding the impact of systemic lupus erythematosus on work amongst South Asian people in the UK: An explorative qualitative study
Lupus, 2021, 30, 1492-1501
1.79Citations (PDF)
58Distinct patterns of disease activity over time in patients with active SLE revealed using latent class trajectory models
Arthritis Research and Therapy, 2021, 23,
3.910Citations (PDF)
59The impact of the COVID-19 pandemic on the medical care and health-care behaviour of patients with lupus and other systemic autoimmune diseases: a mixed methods longitudinal study
Rheumatology Advances in Practice, 2021, 5,
0.731Citations (PDF)
60Epidemiology of disease-activity related ophthalmological manifestations in Systemic Lupus Erythematosus: A systematic review
Lupus, 2021, 30, 2191-2203
1.78Citations (PDF)
61Dietary Omega Polyunsaturated Fatty Acid Intake and Patient‐Reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program
Arthritis Care and Research, 2020, 72, 874-881
2.843Citations (PDF)
62Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus
Journal of Rheumatology, 2020, 47, 72-81
2.356Citations (PDF)
63Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
Arthritis and Rheumatology, 2020, 72, 67-77
6.162Citations (PDF)
64Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach
Arthritis Care and Research, 2020, 72, 1800-1808
2.830Citations (PDF)
65Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index
Arthritis and Rheumatology, 2020, 72, 658-666
6.141Citations (PDF)
66Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus
Journal of Autoimmunity, 2020, 106, 102340
6.640Citations (PDF)
67Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach
Annals of the Rheumatic Diseases, 2020, 79, 356-362
6.971Citations (PDF)
68Medications in pregnancy and breastfeeding
Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 64, 68-76
3.817Citations (PDF)
69Is it me? The impact of patient–physician interactions on lupus patients’ psychological well-being, cognition and health-care-seeking behaviour
Rheumatology Advances in Practice, 2020, 4,
0.755Citations (PDF)
70Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan
Trials, 2020, 21,
2.04Citations (PDF)
71Flares in patients with systemic lupus erythematosus
Rheumatology, 2020, 60, 3262-3267
1.99Citations (PDF)
72Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort
Arthritis and Rheumatology, 2020, 72, 1734-1740
6.124Citations (PDF)
73Medically explained symptoms: a mixed methods study of diagnostic, symptom and support experiences of patients with lupus and related systemic autoimmune diseases
Rheumatology Advances in Practice, 2020, 4,
0.763Citations (PDF)
74Cancer and Systemic Lupus Erythematosus
Rheumatic Disease Clinics of North America, 2020, 46, 533-550
2.345Citations (PDF)
75‘But you don’t look sick’: a qualitative analysis of the LUPUS UK online forum
Rheumatology International, 2020, 41, 721-732
2.432Citations (PDF)
76The Incidence and Prevalence of Adult Primary Sjögren's Syndrome in New York County
Arthritis Care and Research, 2019, 71, 949-960
2.855Citations (PDF)
77Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort
Arthritis Care and Research, 2019, 71, 893-902
2.884Citations (PDF)
789. Successful use of IL-6 pathway blockade to treat autoinflammation occurring in the context of a novel TNFRS1A gene mutation
Rheumatology Advances in Practice, 2019, 3,
0.70Citations (PDF)
79233 Enhancing quality improvement capacity through the British Society for Rheumatology’s multi-region audit into the management of adults with systemic lupus erythematosus
Rheumatology, 2019, 58,
1.91Citations (PDF)
80Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme
Rheumatology Advances in Practice, 2019, 3,
0.710Citations (PDF)
81Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort
Journal of Rheumatology, 2019, 46, 492-500
2.322Citations (PDF)
82Stratifying management of rheumatic disease for pregnancy and breastfeeding
Nature Reviews Rheumatology, 2019, 15, 391-402
25.561Citations (PDF)
83I061 Cancer and lupus: what are the links and what should we be looking out for?
Rheumatology, 2019, 58,
1.90Citations (PDF)
84I082 To stop or not to stop? The effect of anti-rheumatic drugs in pregnancy
Rheumatology, 2019, 58,
1.90Citations (PDF)
85I095 Management of lupus in pregnancy
Rheumatology, 2019, 58,
1.90Citations (PDF)
86I066 Pre-conception counselling in rheumatic disease
Rheumatology, 2019, 58,
1.90Citations (PDF)
87Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus
Arthritis and Rheumatology, 2019, 71, 1297-1307
6.148Citations (PDF)
88Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen
Rheumatology, 2019, 58, 1259-1267
1.911Citations (PDF)
89Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial
BMJ Open, 2019, 9, e032569
1.945Citations (PDF)
90Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort
Annals of the Rheumatic Diseases, 2019, 78, 1010-1012
6.920Citations (PDF)
91Current challenges in the development of new treatments for lupus
Annals of the Rheumatic Diseases, 2019, 78, 729-735
6.945Citations (PDF)
92Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
Arthritis and Rheumatology, 2019, 71, 281-289
6.190Citations (PDF)
93Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry
Arthritis Care and Research, 2019, 71, 95-103
2.852Citations (PDF)
94Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus — Fulton and DeKalb Counties, Georgia, 2002–2016
Morbidity and Mortality Weekly Report, 2019, 68, 419-422
11.496Citations (PDF)
95Prescription Opioid Use in Patients With and Without Systemic Lupus Erythematosus — Michigan Lupus Epidemiology and Surveillance Program, 2014–2015
Morbidity and Mortality Weekly Report, 2019, 68, 819-824
11.425Citations (PDF)
96Obituary for Paul Bacon
Rheumatology, 2018, 57, 943-945
1.90Citations (PDF)
97Efficacy of Epratuzumab, an Anti‐CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome
Arthritis and Rheumatology, 2018, 70, 763-773
6.164Citations (PDF)
98Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus
Journal of Rheumatology, 2018, 45, 393-396
2.339Citations (PDF)
99Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort
Rheumatology, 2018, 57, 677-687
1.950Citations (PDF)
100Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
Arthritis Care and Research, 2018, 70, 1478-1487
2.871Citations (PDF)
101The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary
Rheumatology, 2018, 57, 14-18
1.947Citations (PDF)
102Short-term efficacy and safety of rituximab therapy in refractory systemic lupus erythematosus: results from the British Isles Lupus Assessment Group Biologics Register
Rheumatology, 2018, 57, 470-479
1.989Citations (PDF)
103The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults
Rheumatology, 2018, 57, e1-e45
1.9325Citations (PDF)
104Differences in the diagnosis and management of systemic lupus erythematosus by primary care and specialist providers in the American Indian/Alaska Native population
Lupus, 2018, 27, 1169-1176
1.710Citations (PDF)
105Epratuzumab for the treatment of systemic lupus erythematosus
Expert Review of Clinical Immunology, 2018, 14, 245-258
3.546Citations (PDF)
106Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach
Arthritis Care and Research, 2018, 70, 1294-1302
2.827Citations (PDF)
107126 Cross sectional validation of BILAG2004-Pregnancy Index
Rheumatology, 2018, 57,
1.90Citations (PDF)
108O21 BILAG2004-Pregnancy index is sensitive to change
Rheumatology, 2018, 57,
1.90Citations (PDF)
109A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
Annals of the Rheumatic Diseases, 2017, 76, 554-561
6.9335Citations (PDF)
110Increased Incidence of Gastrointestinal Side Effects in Patients Taking Hydroxychloroquine: A Brand-related Issue?
Journal of Rheumatology, 2017, 44, 398.1-398
2.381Citations (PDF)
111The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program
Arthritis and Rheumatology, 2017, 69, 2006-2017
6.1169Citations (PDF)
112The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project
Arthritis and Rheumatology, 2017, 69, 1996-2005
6.1169Citations (PDF)
113The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales
Rheumatology, 2017, 56, 1041-1043
1.92Citations (PDF)
114Post Hoc Analysis of the Phase II/III APRIL‐SLE Study: Association Between Response to Atacicept and Serum Biomarkers Including BLyS and APRIL
Arthritis and Rheumatology, 2017, 69, 122-130
6.152Citations (PDF)
115Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double‐Blind, Placebo‐Controlled Trials
Arthritis and Rheumatology, 2017, 69, 362-375
6.1233Citations (PDF)
116The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales
Rheumatology, 2017, 56, 1049-1049
1.93Citations (PDF)
117Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study
Arthritis Research and Therapy, 2017, 19,
3.91Citations (PDF)
11813. Progress of Pregnancies in a Patient with Previously Treated Thrombotic Thrombocytopaenic Purpura and Lupus
Rheumatology Advances in Practice, 2017, 1,
0.70Citations (PDF)
119I107 How Does Rheumatic Disease Affect Family Planning and Pregnancy?
Rheumatology, 2016, ,
1.90Citations (PDF)
120A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach
Arthritis and Rheumatology, 2016, 68, 1932-1944
6.145Citations (PDF)
121Incidence of End‐Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry
Arthritis Care and Research, 2016, 68, 357-365
2.842Citations (PDF)
122Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus
Arthritis Care and Research, 2016, 68, 1505-1513
2.851Citations (PDF)
123Systemic lupus erythematosus
Nature Reviews Disease Primers, 2016, 2,
46.91,203Citations (PDF)
124BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids: Table 1
Rheumatology, 2016, 55, 1693-1697
1.9415Citations (PDF)
125BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding—Part II: analgesics and other drugs used in rheumatology practice: Table 1
Rheumatology, 2016, 55, 1698-1702
1.9150Citations (PDF)
126From BILAG to BILAG-based combined lupus assessment—30 years on
Rheumatology, 2016, 55, 1357-1363
1.928Citations (PDF)
127The frequency and outcome of lupus nephritis: results from an international inception cohort study
Rheumatology, 2016, 55, 252-262
1.9563Citations (PDF)
128Hydroxychloroquine-related retinal toxicity
Rheumatology, 2016, 55, 957-967
1.990Citations (PDF)
129Systemic lupus erythematosus: An update for ophthalmologists
Survey of Ophthalmology, 2016, 61, 65-82
5.035Citations (PDF)
130Lupus nephritis management guidelines compared
Nephrology Dialysis Transplantation, 2016, 31, 904-913
0.8106Citations (PDF)
131Population-based Indian Health Service Lupus Registry Finds High Prevalence of Systemic Lupus Erythematosus Among AI/AN Women.
International Journal of Epidemiology, 2015, 44, i34-i34
4.90Citations (PDF)
132Incidence and Prevalence of Systemic Lupus Erythematosus Among Arab and Chaldean Americans in Southeastern Michigan: The Michigan Lupus Epidemiology and Surveillance Program
American Journal of Public Health, 2015, 105, e74-e79
2.837Citations (PDF)
133E89. The Disease-Specific Lupusqol is Sensitive to Change In Patients with Moderate or Severe Systemic Lupus Erythematosus after Treatment of a Flare
Rheumatology, 2015, ,
1.90Citations (PDF)
134290. Long-Term Outcome of Treatment with Mycophenolate Mofetil for Lupus Nephritis
Rheumatology, 2015, ,
1.90Citations (PDF)
135The efficacy and safety of rituximab in a chart review study of 15 patients with systemic lupus erythematosus
Clinical Rheumatology, 2015, 34, 263-271
2.220Citations (PDF)
136Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
Arthritis and Rheumatology, 2015, 67, 1837-1847
6.1118Citations (PDF)
137Electrocardiographic Findings in Systemic Lupus Erythematosus: Data From an International Inception Cohort
Arthritis Care and Research, 2015, 67, 128-135
2.843Citations (PDF)
138Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
Annals of the Rheumatic Diseases, 2015, 74, 2006-2015
6.9280Citations (PDF)
139Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
Annals of the Rheumatic Diseases, 2015, 74, 1530-1536
6.978Citations (PDF)
140Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years
Rheumatology, 2015, 54, 836-843
1.9106Citations (PDF)
141Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort
Annals of the Rheumatic Diseases, 2015, 74, 1706-1713
6.9506Citations (PDF)
142SU‐E‐T‐138: Automated Chart Review Module Including Cross‐Vendor Data Transfer Verification Developed for IHE‐RO Initiative
Medical Physics, 2015, 42, 3363-3363
3.10Citations (PDF)
143Evaluation of Epratuzumab as a Biologic Therapy in Systemic Lupus Erythematosus
Immunotherapy, 2014, 6, 1165-1175
1.98Citations (PDF)
144The Incidence and Prevalence of Systemic Lupus Erythematosus, 2002–2004: The Georgia Lupus Registry
Arthritis and Rheumatology, 2014, 66, 357-368
6.1322Citations (PDF)
145Family planning and pregnancy issues for women with systemic inflammatory diseases: patient and physician perspectives
BMJ Open, 2014, 4, e004081
1.984Citations (PDF)
146Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study
Annals of the Rheumatic Diseases, 2014, 73, 183-190
6.9310Citations (PDF)
147Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006
Rheumatology, 2014, 53, 502-511
1.966Citations (PDF)
148The cost of care of systemic lupus erythematosus (SLE) in the UK: annual direct costs for adult SLE patients with active autoantibody-positive disease
Lupus, 2014, 23, 273-283
1.730Citations (PDF)
149Advances in the assessment of lupus disease activity and damage
Current Opinion in Rheumatology, 2014, 26, 510-519
3.629Citations (PDF)
150Population‐Based Incidence and Prevalence of Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program
Arthritis and Rheumatology, 2014, 66, 369-378
6.1401Citations (PDF)
151Lymphoma risk in systemic lupus: effects of disease activity versus treatment
Annals of the Rheumatic Diseases, 2014, 73, 138-142
6.9142Citations (PDF)
152Treat-to-target in systemic lupus erythematosus: recommendations from an international task force
Annals of the Rheumatic Diseases, 2014, 73, 958-967
6.9689Citations (PDF)
153Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS)
Rheumatology, 2014, 53, 275-284
1.986Citations (PDF)
154Interferon-α-induced B-lymphocyte stimulator expression and mobilization in healthy and systemic lupus erthymatosus monocytes
Rheumatology, 2014, 53, 2249-2258
1.953Citations (PDF)
155American College of Rheumatology Criteria at Inception, and Accrual over 5 Years in the SLICC Inception Cohort
Journal of Rheumatology, 2014, 41, 875-880
2.334Citations (PDF)
15625‐Hydroxyvitamin D and Cardiovascular Disease in Patients With Systemic Lupus Erythematosus: Data From a Large International Inception Cohort
Arthritis Care and Research, 2014, 66, 1167-1176
2.854Citations (PDF)
157Prevalence and Incidence of Systemic Lupus Erythematosus in a Population‐Based Registry of American Indian and Alaska Native People, 2007–2009
Arthritis and Rheumatology, 2014, 66, 2494-2502
6.1121Citations (PDF)
158Systemic Lupus Erythematosus and Malignancies
Rheumatic Disease Clinics of North America, 2014, 40, 497-506
2.329Citations (PDF)
159Sustained Improvements In Health-Related Quality Of Life In Patients With Systemic Lupus Erythematosus Following Epratuzumab TreatmentResults From A Phase Iib Study And Its Open-Label Extension
Value in Health, 2014, 17, A232-A233
1.91Citations (PDF)
160Cancer risk in systemic lupus: An updated international multi-centre cohort study
Journal of Autoimmunity, 2013, 42, 130-135
6.6296Citations (PDF)
161Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study
Arthritis and Rheumatism, 2013, 65, 2887-2897
6.1103Citations (PDF)
162Pulmonary arterial hypertension in SLE: what do we know?
Lupus, 2013, 22, 1274-1285
1.728Citations (PDF)
163B-Cell Targeted Therapies in Systemic Lupus Erythematosus
BioDrugs, 2013, 27, 85-95
6.241Citations (PDF)
164New biologic therapy for systemic lupus erythematosus
Current Opinion in Pharmacology, 2013, 13, 405-412
3.826Citations (PDF)
165Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis
BMJ Open, 2013, 3, e002852
1.920Citations (PDF)
166Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
Annals of the Rheumatic Diseases, 2013, 72, 1308-1314
6.986Citations (PDF)
167Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up
Rheumatology, 2013, 52, 1313-1322
1.9123Citations (PDF)
168In Utero Azathioprine Exposure and Increased Utilization of Special Educational Services in Children Born to Mothers With Systemic Lupus Erythematosus
Arthritis Care and Research, 2013, 65, 759-766
2.847Citations (PDF)
169Managing Lupus Nephritis in Pregnant Women: Comment on the Article by Hahn et al
Arthritis Care and Research, 2013, 65, 1391-1392
2.80Citations (PDF)
170The substantial burden of systemic lupus erythematosus on the productivity and careers of patients: a European patient-driven online survey
Rheumatology, 2013, 52, 2292-2301
1.991Citations (PDF)
171Malignancies in systemic lupus erythematosus
International Journal of Clinical Rheumatology, 2013, 8, 275-280
0.40Citations (PDF)
172Clinical Pharmacology and Modification of Autoimmunity and Inflammation in Rheumatoid Disease
Drugs, 2012, 47, 259-285
11.41Citations (PDF)
173Systemic lupus and malignancies
Current Opinion in Rheumatology, 2012, 24, 177-181
3.639Citations (PDF)
174Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study
Annals of the Rheumatic Diseases, 2012, 71, 1502-1509
6.9162Citations (PDF)
175Decreased breast cancer risk in systemic lupus erythematosus: the search for a genetic basis continues
Lupus, 2012, 21, 896-899
1.727Citations (PDF)
176The BILAG2004-Pregnancy index is reliable for assessment of disease activity in pregnant SLE patients
Rheumatology, 2012, 51, 1877-1880
1.932Citations (PDF)
177The BILAG-2004 systems tally—a novel way of representing the BILAG-2004 index scores longitudinally
Rheumatology, 2012, 51, 2099-2105
1.915Citations (PDF)
178Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis
Annals of the Rheumatic Diseases, 2012, 71, 1771-1782
6.9959Citations (PDF)
179Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
Arthritis and Rheumatism, 2012, 64, 2677-2686
6.14,818Citations (PDF)
180Refractory multisystem sarcoidosis responding to infliximab therapy
Clinical Rheumatology, 2012, 31, 1013-1018
2.218Citations (PDF)
181Managing pregnancy in inflammatory rheumatological diseases
Arthritis Research and Therapy, 2011, 13, 206
3.955Citations (PDF)
182Causes and management of infertility in systemic lupus erythematosus
Rheumatology, 2011, 50, 1551-1558
1.980Citations (PDF)
183PSY45 Impact of Lupus on Career Choices and Work productivity in Five European Countries: Results from the Lupus European Online (Leo) Survey
Value in Health, 2011, 14, A418
1.90Citations (PDF)
184Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)
Lupus, 2011, 20, 709-716
1.7124Citations (PDF)
185Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-analysis
British Journal of Cancer, 2011, 104, 1478-1481
5.591Citations (PDF)
186The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients
Rheumatology, 2011, 50, 982-988
1.9188Citations (PDF)
187Pregnancy and reproduction in autoimmune rheumatic diseases
Rheumatology, 2011, 50, 657-664
1.9122Citations (PDF)
188‘It’s like taking poison to kill poison but I have to get better’: A qualitative study of beliefs about medicines in Rheumatoid arthritis and Systemic lupus erythematosus patients of South Asian origin
Lupus, 2011, 20, 837-844
1.767Citations (PDF)
189Systemic lupus erythematosus
Medicine, 2010, 38, 73-80
0.482Citations (PDF)
190Systemic lupus erythematosus: Clinical presentations
Autoimmunity Reviews, 2010, 10, 43-45
7.1123Citations (PDF)
191Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: Findings in a multicenter, prospective, randomized, open‐label, parallel‐group clinical trial
Arthritis and Rheumatism, 2010, 62, 211-221
6.1153Citations (PDF)
192Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
Arthritis and Rheumatism, 2010, 62, 222-233
6.11,329Citations (PDF)
193Numerical scoring for the BILAG-2004 index
Rheumatology, 2010, 49, 1665-1669
1.9135Citations (PDF)
194The LupusQoL and Associations with Demographics and Clinical Measurements in Patients with Systemic Lupus Erythematosus
Journal of Rheumatology, 2010, 37, 2273-2279
2.365Citations (PDF)
195SLE and Antiphospholipid Syndrome [223-231]: 223. Acid Disruption Biacore Analysis of Antibodies Against Rituximab in SLE Patients
Rheumatology, 2010, 49, i119-i122
1.90Citations (PDF)
196Contemporary treatment of systemic lupus erythematosus: an update for clinicians
Therapeutic Advances in Chronic Disease, 2010, 1, 163-175
2.467Citations (PDF)
197The BILAG multi-centre open randomized controlled trial comparing ciclosporin vs azathioprine in patients with severe SLE
Rheumatology, 2010, 49, 723-732
1.986Citations (PDF)
198Endometriosis
BMJ: British Medical Journal, 2010, 340, c2168-c2168
0.127Citations (PDF)
199Clinical trials in lupus: what have we learned so far?
Rheumatology, 2010, 49, 1025-1027
1.917Citations (PDF)
200Risk Factors for Clinical Coronary Heart Disease in Systemic Lupus Erythematosus: The Lupus and Atherosclerosis Evaluation of Risk (LASER) Study
Journal of Rheumatology, 2010, 37, 322-329
2.390Citations (PDF)
201Numerical scoring for the Classic BILAG index
Rheumatology, 2009, 48, 1548-1552
1.937Citations (PDF)
202Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus
Rheumatology, 2009, 48, 1506-1511
1.9122Citations (PDF)
203Adverse events and efficacy of TNF-  blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients
Rheumatology, 2009, 48, 1451-1454
1.9187Citations (PDF)
204The BILAG-2004 index is sensitive to change for assessment of SLE disease activity
Rheumatology, 2009, 48, 691-695
1.9101Citations (PDF)
205EULAR points to consider for conducting clinical trials in systemic lupus erythematosus
Annals of the Rheumatic Diseases, 2009, 68, 470-476
6.941Citations (PDF)
206Lupus and cancer
Lupus, 2009, 18, 479-485
1.784Citations (PDF)
207Assessment of disease activity and quality of life in systemic lupus erythematosus – New aspects
Best Practice and Research in Clinical Rheumatology, 2009, 23, 457-467
3.936Citations (PDF)
208Challenges of ethnicity in SLE
Best Practice and Research in Clinical Rheumatology, 2009, 23, 549-561
3.930Citations (PDF)
209Experience with a Punjabi, Urdu and Hindi rheumatology telephone helpline
Musculoskeletal Care, 2009, 7, 210-218
1.611Citations (PDF)
210Biologic therapy and pregnancy outcomes in women with rheumatic diseases
Arthritis Care and Research: the Official Journal of the Arthritis Health Professions Association, 2009, 61, 587-592
5.771Citations (PDF)
211Population‐based lupus registries: Advancing our epidemiologic understanding
Arthritis Care and Research: the Official Journal of the Arthritis Health Professions Association, 2009, 61, 1462-1466
5.766Citations (PDF)
212Anti-TNF therapy and pregnancy outcomes in women with inflammatory arthritis
Expert Review of Clinical Immunology, 2009, 5, 27-34
3.57Citations (PDF)
213SLE patients with renal damage incur higher health care costs
Rheumatology, 2008, 47, 329-333
1.974Citations (PDF)
214Testosterone patches in the management of patients with mild/moderate systemic lupus erythematosus
Rheumatology, 2008, 47, 334-338
1.946Citations (PDF)
215Systemic lupus international collaborating clinics renal activity/response exercise: Development of a renal activity score and renal response index
Arthritis and Rheumatism, 2008, 58, 1784-1788
6.167Citations (PDF)
216Systemic lupus international collaborating clinics renal activity/response exercise: Comparison of agreement in rating renal response
Arthritis and Rheumatism, 2008, 58, 1789-1795
6.116Citations (PDF)
217Systemic lupus erythematosus in women: Impact on family size
Arthritis Care and Research: the Official Journal of the Arthritis Health Professions Association, 2008, 59, 1656-1660
5.728Citations (PDF)
218Urinary IL-6: a marker for mesangial proliferative glomerulonephritis?
Clinical and Experimental Immunology, 2008, 86, 145-149
3.316Citations (PDF)
219Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future – the EULAR recommendations for the management of SLE and the use of end-points in clinical trials
Lupus, 2008, 17, 437-442
1.757Citations (PDF)
220Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin
Rheumatology, 2008, 47, 690-697
1.9102Citations (PDF)
221Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs
Rheumatology, 2008, 47, iii28-iii31
1.9116Citations (PDF)
222Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists
Rheumatology, 2007, 46, 1438-1440
1.9139Citations (PDF)
223Pregnancy and rheumatic diseases
Rheumatology, 2007, 46, 1634-1640
1.976Citations (PDF)
224Direct healthcare costs and predictors of costs in patients with primary Sjogren's syndrome
Rheumatology, 2007, 46, 105-111
1.978Citations (PDF)
225Ocular manifestations of systemic lupus erythematosus
Rheumatology, 2007, 46, 1757-1762
1.9209Citations (PDF)
226The systemic lupus erythematosus Tri-Nation study: Cumulative indirect costs
Arthritis and Rheumatism, 2007, 57, 64-70
6.163Citations (PDF)
227Tumor necrosis factor α activates release of B lymphocyte stimulator by neutrophils infiltrating the rheumatoid joint
Arthritis and Rheumatism, 2007, 56, 1776-1786
6.168Citations (PDF)
228Development and validation of a disease‐specific health‐related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus
Arthritis Care and Research: the Official Journal of the Arthritis Health Professions Association, 2007, 57, 972-979
5.7288Citations (PDF)
229British isles lupus assessment group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus
Arthritis and Rheumatism, 2007, 56, 4113-4119
6.1105Citations (PDF)
230Title is missing!
Arthritis Research and Therapy, 2006, 8, R120
3.984Citations (PDF)
231Title is missing!
Arthritis Research and Therapy, 2006, 8, 209
3.9505Citations (PDF)
232Clinical significance of IgA anticardiolipin and anti-β2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome
Clinical Rheumatology, 2006, 25, 199-204
2.256Citations (PDF)
233Large vessel vasculitides
Medicine, 2006, 34, 468-471
0.43Citations (PDF)
234Usefulness of the British Isles Lupus Assessment Group index in pediatric clinical trials: Comment on the article by Ruperto et al
Arthritis and Rheumatism, 2006, 54, 2343-2344
6.11Citations (PDF)
235Revised British Isles Lupus Assessment Group 2004 index: A reliable tool for assessment of systemic lupus erythematosus activity
Arthritis and Rheumatism, 2006, 54, 3300-3305
6.1105Citations (PDF)
236Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case–control study
Arthritis and Rheumatism, 2006, 55, 892-899
6.198Citations (PDF)
237Development of an interactive learning tool for teaching rheumatology—a simulated clinical case studies program*
Rheumatology, 2006, 45, 1158-1161
1.932Citations (PDF)
238A statistical analysis of the interrelationships between disease activity in different systems in systemic lupus erythematosus
Rheumatology, 2006, 45, 308-313
1.912Citations (PDF)
239Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices
Best Practice and Research in Clinical Rheumatology, 2005, 19, 685-708
3.9303Citations (PDF)
240Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin
Arthritis Research and Therapy, 2005, 7,
3.9446Citations (PDF)
241Shiga-toxin-producing and haemolytic uraemic syndrome
Lancet, The, 2005, 365, 1073-1086
62.11,219Citations (PDF)
242Sequential Therapies for Proliferative Lupus Nephritis
New England Journal of Medicine, 2004, 350, 2518-2520
34.52Citations (PDF)
243Malignancy is increased in ANCA-associated vasculitis
British Journal of Rheumatology, 2004, 43, 1532-1535
2.1157Citations (PDF)
244Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus
British Journal of Rheumatology, 2004, 43, 1178-1181
2.129Citations (PDF)
245Factors associated with abnormal Pap results in systemic lupus erythematosus
British Journal of Rheumatology, 2004, 43, 1386-1389
2.162Citations (PDF)
246Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology?
Clinical and Experimental Immunology, 2004, 138, 348-356
3.352Citations (PDF)
247Pregnancy and autoimmune diseases
Best Practice and Research in Clinical Rheumatology, 2004, 18, 359-379
3.964Citations (PDF)
248Measuring systemic lupus erythematosus activity during pregnancy: Validation of the lupus activity index in pregnancy scale
Arthritis and Rheumatism, 2004, 51, 78-82
6.171Citations (PDF)
249Pregnancy and autoimmune diseases
Best Practice and Research in Clinical Rheumatology, 2004, 18, 359-379
3.918Citations (PDF)
250Clinical uses and misuses of dehydroepiandrosterone
Current Opinion in Pharmacology, 2003, 3, 635-641
3.822Citations (PDF)
251Lupus and zoster
Lancet, The, 2003, 362, 616
62.15Citations (PDF)
252Association of damage with autoantibody profile, age, race, sex and disease duration in systemic lupus erythematosus
British Journal of Rheumatology, 2003, 42, 276-279
2.181Citations (PDF)
253Cardiovascular risk in systemic lupus erythematosus--evidence of increased oxidative stress and dyslipidaemia
British Journal of Rheumatology, 2003, 42, 758-762
2.185Citations (PDF)
254Definition and treatment of lupus flares measured by the BILAG index
British Journal of Rheumatology, 2003, 42, 1372-1379
2.1132Citations (PDF)
255Use of patient age and anti-Ro/La antibody status to determine the probability of patients with systemic lupus erythematosus and sicca symptoms fulfilling criteria for secondary Sjogren's syndrome
British Journal of Rheumatology, 2003, 42, 189-191
2.110Citations (PDF)
256Ultrasound guidance allows accurate needle placement and aspiration from small joints in patients with early inflammatory arthritis
British Journal of Rheumatology, 2003, 42, 976-979
2.1171Citations (PDF)
257Antiphospholipid syndrome in an eight-month-old infant with sickle cell trait
British Journal of Rheumatology, 2002, 41, 697-698
2.11Citations (PDF)
258Long-term complications of systemic lupus erythematosus
British Journal of Rheumatology, 2002, 41, 1095-1100
2.166Citations (PDF)
259Management of pregnancy in women with pulmonary hypertension secondary to SLE and anti-phospholipid syndrome
Lupus, 2002, 11, 392-398
1.755Citations (PDF)
260Primary Anti-Phospholipid Antibody Syndrome (APS)
Survey of Ophthalmology, 2002, 47, 215-238
5.088Citations (PDF)
261Large Vessel Vasculitides (including Polymyalgia Rheumatica)
Medicine, 2002, 30, 26-29
0.40Citations (PDF)
262Candidate T cell epitopes of the human La/SSB autoantigen
Arthritis and Rheumatism, 2002, 46, 209-214
6.128Citations (PDF)
263A nonsense mutation in exon 2 of the DNase I gene is not present in UK subjects with systemic lupus erythematosus and Graves' disease: Comment on the article by Rood et al
Arthritis and Rheumatism, 2002, 46, 3109-3110
6.125Citations (PDF)
264Systemic Lupus Erythematosus and the Menopause
The Journal of the British Menopause Society, 2001, 7, 135-136
0.80Citations (PDF)
265Update on systemic lupus erythematosus: autoantibodies and apoptosis
Clinical Medicine, 2001, 1, 10-14
1.333Citations (PDF)
266IgG subclass distribution of antibodies against β2‐GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations
Rheumatology, 2001, 40, 1026-1032
1.931Citations (PDF)
267The use of alternative medical therapies in patients with systemic lupus erythematosus
Arthritis and Rheumatism, 2000, 43, 1410-1418
6.161Citations (PDF)
268Trainable rule-based algorithm for the measurement of joint space width in digital radiographic images of the knee
Medical Physics, 2000, 27, 580-591
3.1127Citations (PDF)
269Lupus patients with fatigue--is there a link with fibromyalgia syndrome?
British Journal of Rheumatology, 2000, 39, 620-623
2.148Citations (PDF)
270From BILAG to BLIPS—disease activity assessment in lupus past, present and future
Lupus, 2000, 9, 651-654
1.799Citations (PDF)
271Antioxidant properties of colchicine in acute carbon tetrachloride induced rat liver injury and its role in the resolution of established cirrhosis
Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2000, 1502, 351-362
4.132Citations (PDF)
272The role of apoptosis in systemic lupus erythematosus
Rheumatology, 1999, 38, 1177-1183
1.940Citations (PDF)
273Postgraduate degrees for rheumatology trainees: an options appraisal of MD, PhD and MSc degrees
Rheumatology, 1999, 38, 1290-1293
1.910Citations (PDF)
274Quality of life and economic evaluation in SLE clinical trials
Lupus, 1999, 8, 645-654
1.737Citations (PDF)
275The association of socio-economic status, race, psychosocial factors and outcome in patients with systemic lupus erythematosus
Rheumatology, 1999, 38, 1130-1137
1.9124Citations (PDF)
276The Interleukin-1 Receptor Antagonist Gene Shows No Allelic Association with Three Autoimmune Diseases
Thyroid, 1999, 9, 627-628
4.418Citations (PDF)
277Factors Involved in the Pathogenesis of Neutrophilic Vasculitis in MRL/Mp- lpr/lpr Mice: A Model for Human Microscopic Angiitis
Autoimmunity, 1999, 31, 133-145
3.16Citations (PDF)
278Overrepresentation of the Fc? receptor type IIA R131/R131 genotype in Caucasoid systemic lupus erythematosus patients with autoantibodies to C1q and glomerulonephritis
Arthritis and Rheumatism, 1999, 42, 1828-1832
6.187Citations (PDF)
279The treatment of refractory uveitis with intravenous immunoglobulin
American Journal of Ophthalmology, 1999, 127, 545-549
3.859Citations (PDF)
280Antidepressants for old people
BMJ: British Medical Journal, 1999, 319, 849-849
0.11Citations (PDF)
281No evidence for allelic association of a human CTLA‐4 promoter polymorphism with autoimmune thyroid disease in either population‐based case–control or family‐based studies
Clinical Endocrinology, 1998, 49, 331-334
2.358Citations (PDF)
282Intravenous immunoglobulin therapy in compromised pregnancies associated with antiphospholipid antibodies and systemic lupus erythematosus
European Journal of Obstetrics, Gynecology and Reproductive Biology, 1998, 79, 227-229
0.920Citations (PDF)
283Use of intravenous immunoglobulin therapy in pregnancy in systemic lupus erythematosus and antiphospholipid antibody syndrome
Lupus, 1998, 7, 429-433
1.728Citations (PDF)
284Damage occurs early in systemic vasculitis and is an index of outcome
QJM - Monthly Journal of the Association of Physicians, 1997, 90, 391-399
0.5109Citations (PDF)
285Development and initial validation of the vasculitis damage index for the standardized clinical assessment of damage in the systemic vasculitides
Arthritis and Rheumatism, 1997, 40, 371-380
6.1580Citations (PDF)
286The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus
Arthritis and Rheumatism, 1997, 40, 809-813
6.1637Citations (PDF)
287Systemic lupus erythematosus complicated by antiphospholipid antibody syndrome
BMJ: British Medical Journal, 1997, 314, 1349
0.10Citations (PDF)
288Undiagnosed systemic lupus erythematosus in the community
Lancet, The, 1996, 347, 367-369
62.146Citations (PDF)
289ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS IS ASSOCIATED WITH THE RECRUITMENT OF NAIVE/RESTING T CELLS
Rheumatology, 1996, 35, 226-230
1.933Citations (PDF)
290The prevalence and incidence of systemic lupus erythematosus in Birmingham, England
Arthritis and Rheumatism, 1995, 38, 551-558
6.1342Citations (PDF)
291Rheumatic diseases in pregnancy
Current Obstetrics & Gynaecology, 1995, 5, 163-168
0.22Citations (PDF)
292Cross-Sectional Analysis of the Differences Between Patients with Systemic Lupus Erythematosus in England, Brazil and Sweden
Lupus, 1994, 3, 501-506
1.727Citations (PDF)
293A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha
European Journal of Immunology, 1994, 24, 191-195
3.1214Citations (PDF)
294Interleukin–1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus
Arthritis and Rheumatism, 1994, 37, 1380-1385
6.1271Citations (PDF)
295CORRELATION OF BLOOD LEVELS OF SOLUBLE VASCULAR CELL ADHESION MOLECULE-1 WITH DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS AND VASCULITIS
Rheumatology, 1994, 33, 1112-1116
1.979Citations (PDF)
296DISEASE‐MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATOID ARTHRITIS: CURRENT CONCEPTS
International Journal of Clinical Practice, 1994, 48, 82-86
3.04Citations (PDF)
297Cytokine gene polymorphisms in inflammatory dermatoses
Journal of Dermatological Science, 1993, 6, 18
2.30Citations (PDF)
298Assessment of lupus: where are we now?
Annals of the Rheumatic Diseases, 1993, 52, 169-172
6.922Citations (PDF)
299Dr de Vries' letter was shown to Dr Emery and colleagues who reply:
Rheumatology, 1993, 32, 172-172
1.94Citations (PDF)
300TWO CASES OF ‘WEGENER’S TUBERCULOSIS'
Rheumatology, 1993, 32, 143-149
1.918Citations (PDF)
301Antibodies to protein P in systemic lupus erythematosus.
Annals of the Rheumatic Diseases, 1992, 51, 489-494
6.971Citations (PDF)
302Carbocisteine polymorphism and disease
Lancet, The, 1992, 339, 616-617
62.17Citations (PDF)
303Chronic therapy with recombinant tumor necrosis factor-α in autoimmune NZB/NZW F1 mice
Clinical Immunology and Immunopathology, 1989, 52, 421-434
1.8163Citations (PDF)
304Dysphagia in acute stroke.
BMJ: British Medical Journal, 1987, 295, 411-414
0.1578Citations (PDF)
305Leber'S Congenital Amaurosis in Monozygotic Twins
American Journal of Ophthalmology, 1984, 97, 655
3.83Citations (PDF)
306HILL STATIONS IN INDIA.
Lancet, The, 1868, 92, 74-75
62.10Citations (PDF)
307Defining Optimally Safe and Effective Blood Levels of Hydroxychloroquine in Lupus: An Important Step Toward Precision Drug Monitoring
Arthritis and Rheumatology, 0, 78, 1102-1113
6.13Citations (PDF)